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cent transformed cells or inhibiting their outgrowth. This antitu-
mor immunity is substantiated by the main cellular effectors of the 
innate and the adaptive immune system, namely natural killer cells, 
natural killer T cells, and T cells (TCs), as well as increased pro-
immune humoral factors (e.g., interferons) in the tumor microen-
vironment. On the other hand, in the tumor-promoting phase re-
ferred to as ‘immune escape’, the immune system can further 
tumor progression either by selecting cancer cells that are more 
capable of surviving the host’s immunocompetence or by modify-
ing the tumor microenvironment in such a way that tumor out-
growth is facilitated [2]. In between the above phases is the equilib-
rium where cancerous cells are kept under control but are not 
eliminated by the immune system. This balance of antitumor and 
tumor-promoting factors may maintain the tumor in a function-
ally inactive state of dormancy over a period of many years [3].
The processes mentioned above also make up the rationale for 
the development of immunotherapeutic options in breast cancer 
(BC) [3–5], as characteristically in this tumor entity, already at very 
early stages, cancer cells are able to disseminate hematogenously 
from the primary tumor site, and distant metastases often occur 
only after many years of latency [6]. In this context, one predomi-
nant organ associated with the dissemination and survival of BC 
tumor cells is, besides others such as locoregional lymph nodes, the 
bone marrow (BM). Of note, the detection of disseminated BM 
tumor cells correlates with an increased rate of secondary osseous 
and visceral metastases and with a worse overall survival [7–11]. 
Consequently, in addition to surgical resection of the primary 
tumor and locoregional irradiation, curative BC therapy aims at 
eliminating disseminated micrometastatic tumor cells. In this con-
text, besides cytostatic and/or hormonal therapies, new supportive 
treatment options like immunotherapy are increasingly gaining 
oncological interest. Hence, we also review aspects of BC immu-
noediting processes with respect to potential immunotherapeutic 
approaches. 
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Summary
More recently, immunotherapy has emerged as a novel 
potentially effective therapeutic option also for solid 
malignancies such as breast cancer (BC). Relevant ap-
proaches, however, are determined by the 2 main ele-
ments of cancer immunoediting – the elimination of 
nascent transformed cells by immunosurveillance on 
the one hand and tumor immune escape on the other 
hand. Correspondingly, we here review the role of the 
various cellular immune players within the host-protec-
tive system and dissect the mechanisms of immune 
evasion leading to tumor progression. If the immune 
balance of disseminated BC cell dormancy (equilibrium 
phase) is lost, distant metastatic relapse may occur. The 
relevant cellular antitumor responses and translational 
immunotherapeutic options will also be discussed in 
terms of clinical benefit and future directions in BC 
management.
© 2016 S. Karger GmbH, Freiburg
Introduction
An intact immune system plays a dual role in cancer: it can pre-
vent/control as well as shape/promote cancer by a process called 
‘cancer immunoediting’ [1]. On the one hand, in a host-protective 
elimination phase named ‘immunosurveillance’, the immune sys-
tem can recognize and suppress tumor growth by destroying nas-
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Cellular Immune Responses
Tumor Site
In human BCs, like in other malignancies, the presence of pri-
mary tumor-infiltrating lymphocytes (TILs), especially of the Th1 
and cytotoxic variety, is correlated with the absence of metastatic 
invasion and improved clinical outcome in terms of overall sur-
vival rates [12]. This holds particularly true for BCs with aggressive 
features such as high histologic grade or estrogen receptor-α nega-
tivity [13, 14].
Intriguingly, in triple-negative invasive BC patients receiving 
neoadjuvant chemotherapy and subsequent surgical treatment, the 
immunohistochemical or mainly the hematoxylin and eosin stain-
ing analysis of primary tumor needle biopsy specimens revealed 
that the pathologic complete response rates of tumors showing a 
high TIL score were significantly higher than those of tumors with 
a low TIL count [15, 16]. These results suggested that the pretreat-
ment host immune response may enhance the ability of anthracy-
cline/taxane-based neoadjuvant chemotherapy to eliminate cancer 
cells [17]. This hypothesis was further corroborated by large stud-
ies which demonstrated triple-negative as well as HER2-overex-
pressing BC phenotypes with high levels of intratumoral cytotoxic 
TCs to have heightened sensitivity to anthracycline-based chemo-
therapy, as assessed by the immediate response to neoadjuvant 
therapy and long-term disease-free survival rates [18–20]. Further, 
in HER2-positive BC patients, high levels of TILs were also found 
to be associated with improved therapeutic responses to the mono-
clonal antibody trastuzumab [21].
In summary, the data available suggest that particularly in ag-
gressive subtypes such as triple-negative and HER2-positive BC the 
immune response plays a pivotal part in tumor chemosensitivity 
and clinical outcome.
Bone Marrow Site
TCs play a central role in cell-mediated tumor immunity. Con-
ventionally, the precursors of TCs are produced in the BM but sub-
sequently leave the BM and mature in the thymus. Mature cells 
then emigrate from the thymus into the circulation. Repeatedly, 
circulating naive TCs leave the blood to enter peripheral lymphoid 
organs where they may encounter their specific tumor antigen and 
become activated as effector (cytotoxic or helper) TCs.
Relating to BC immunity and the generation of tumor-specific 
effector and memory TCs, blood/BM interactions proceed in 3 
steps [22, 23]:
i) Naive TCs as well as tumor cells are recruited from the circula-
tion to the BM (‘homing’) via constitutively expressed adhesion 
molecules [24, 25]; 
ii) BM-resident antigen-presenting cells, particularly dendritic 
cells, can scan, process, and cross-present BC-associated anti-
gens to prime TCs [22, 26]; and
iii) activated TCs proliferate and may become effector and memory 
cells that either recirculate or remain in the BM compartment.
The coexistence of BM-resident tumor-specific TCs and dis-
seminated BC cells maintains the quiescent state, i.e., the immune 
balance, which is referred to as tumor dormancy, while a loss of TC 
function can lead to tumor metastasis even after years of latency 
[27–30].
Furthermore, especially in the case of BC, in a significant num-
ber of patients during the course of disease, tumor-specific TC re-
sponses could be proven to have been induced and maintained in 
the form of BM memory TCs (TMCs) – a subset of BC-specific 
TCs that persist long-term [31].
TMCs are an ideal source for the generation of therapeutic ef-
fector TCs expressing the CD8 glycoprotein at their surfaces. This 
is due to the fact that secondary CD8+ TC responses take place 
more quickly and more effectively than primary responses [32–34]. 
Correspondingly, in a trial of advanced metastasized BC patients 
with tumor-reactive TMCs in the BM, no tumor-specific TCs were 
detected in the peripheral blood at the beginning. After therapy 
with reactivated autologous BC-reactive BM TMCs, however, 
about 44% of patients showed tumor-specific TCs in the peripheral 
blood [35, 36]. 
Tumor Immune Escape
Mechanisms
In the studies cited above [35, 36], which will be discussed in 
more detail in the subsequent chapters, roughly half of the BC pa-
tients treated did not respond to the immunotherapy employed. In 
these patients, counterregulation mechanisms may have taken ac-
tion leading to post-therapy tumor immune escape along the fol-
lowing lines:
i) The immune recognition of tumor cells can be circumvented 
because of loss of tumor antigen expression that may occur in at 
least 3 ways [2]: through development of tumor cells lacking 
 expression of potent rejection antigens; by means of down-
regulation of major histocompatibility complex (MHC) class I 
proteins that present these antigens to tumor-specific TCs; or 
via loss of tumor cells’ antigen processing capacity that is man-
datory to develop the antigenic peptide epitopes and load them 
onto the MHC class I molecules.
ii) At the tumor cell level, resistance to cytotoxic lysis by immune 
cells may be brought about by enhanced expression of anti- 
apoptotic effector molecules such as FLIP and BCL-XL [37] or 
by persistent activation of pro-oncogenic transcription factors 
like STAT3 [2]. Alternatively, tumor cells can evade immune-
mediated killing through expression of mutated inactive forms 
of death receptors [37]. Concertedly, these mechanisms may 
promote tumor progression.
iii) Tumor immune escape may develop due to local immuno-
suppression in the tumor microenvironment. Such an immuno-
suppressive state can be established either by tumor cells pro-
ducing immunosuppressive cytokines (e.g., vascular endothelial 
growth factor and transforming growth factor-ß (TGF-ß)) or by 
recruitment of specific immunosuppressive leukocyte popula-
tions (e.g., regulatory TCs (Tregs) and myeloid-derived sup-




Clearly, the rate of BC progression is determined by the balance 
between the above immune-inhibitory factors of tumor immune 
escape and the host-protective capacity of the immune system as 
well as the immune-stimulatory conditions of immunotherapeutic 
approaches. 
Potential Anti-Escape Strategies
In BC patients with failed immune response to cellular immu-
notherapeutic approaches, a significantly higher proportion of 
Tregs was found in the BM [35]. Tregs are a subpopulation of TCs 
which generally suppress (hence also called suppressor TCs) or 
downregulate activities of effector TCs thus modulating immune 
reactions, maintaining tolerance to self-antigens, and abrogating 
autoimmune disease. Consequently, in future immunotherapy 
studies, patients might benefit from ex vivo Treg depletion prior to 
TC stimulation.
Additional strategies potentially capable of reducing the immu-
nosuppressive effects of Tregs are currently investigated in murine 
models or first clinical studies and comprise i) denileukin diftitox, 
a fusion protein of interleukin 2 and diphtheria toxin targeting 
Treg cells [39–41], ii) direct antibody blockade of the immunosup-
pressive moieties of Tregs [37, 38], and iii) pharmacological agents 
such as cyclooxygenase-2 inhibitors as well as the antineoplastics 
temozolomide (tumor DNA methylator), fludarabine (purine 
analog), and cyclophosphamide (CTX) [42, 43]. Strikingly, CTX, a 
well-known chemotherapeutic compound, when being applied 
solely at low doses in a metronomic regimen could be demon-
strated to induce a selective profound reduction in circulating 
Tregs through enhanced apoptosis and decreased proliferation of 
this cell type [44, 45]. Simultaneously, spontaneous antitumor TC 
responses were found restored [42, 45].
Correspondingly, in a recent study of metastasized BC patients, 
Ge et al. [46] reported metronomic CTX treatment over 3 months to 
cause a transient reduction in circulating Tregs by more than 40% 
associated with a strong and lasting increase in breast tumor-specific 
TCs, which significantly correlated with disease stabilization and 
overall survival. Consequently, low-dose CTX might be successfully 
integrated into a future concept of chemoimmunotherapy. 
Cellular Immunotherapy
Possible Accesses
Cellular immunotherapy approaches are based on 2 different 
principles [47]:
i) The body’s own immune system can be actively and specifically 
stimulated through confrontation of immune cells with autolo-
gous or allogeneic tumor antigens in situ. This leads to a primary 
activation of naive effector cells or to a secondary reactivation of 
memory cells which were formed during an earlier confronta-
tion of the immune system with the specific antigen. This proce-
dure corresponds to an active immunization, i.e., a vaccination.
ii) Autologous or allogeneic immune cells (tumor-specific TMCs 
from BM [35, 36] or peripheral blood [48], TILs [49], or engi-
neered TCs [50]) with a specific affinity for tumor-associated 
antigens can get activated ex vivo and subsequently applied di-
rectly into the human organism as cellular immunotherapy. 
This is equivalent to a passive immunization, i.e., an adoptive 
immunotherapy (ADI).
Vaccination
Vaccine-based therapies do firstly require the identification of 
tumor-specific antigens (expressed on malignancies only) and 
tumor-associated antigens (expressed on all types of cells but 
overexpressed on cancer cells). In breast cancer, relevant anti-
gens that could be targeted by vaccination include MUC-1, 
MAGE-A3, and NY-ESO-1 which are characteristically ex-
pressed on estrogen receptor-negative and/or triple-negative 
tumor subvariants [51, 52]. In vaccination strategies, liposome-
based and synthetic peptide vaccines are employed. Additionally, 
the administration of in vitro activated dendritic cells can be in-
volved [53]. In BC patients, attempts along the above lines are 
currently being evaluated in clinical trials which are comprehen-
sively expounded elsewhere [54]. 
Adoptive Immunotherapy
Results from animal experiments [55–57] were the rationale for 
the establishment of a phase I trial where patients with advanced 
metastasized BC were treated with reactivated autologous tumor-
specific BM TMCs [35, 36]. In 16 BC patients with tumor-reactive 
BM TMCs, another BM aspiration was performed which provided 
tumor-specific TMCs for the following flow of ADI treatment: 
i) TMCs were activated by antigen-pulsed dendritic cells with an-
tigens originating from lysates of a microbiologically tested 
MCF-7 cell line. After incubation of the antigen-presenting cells 
with TMCs, the cell suspension (2 × 106 to 5.7 × 107 TCs) was 
intravenously applied under antibiotic prophylaxis (fig. 1). This 
Fig. 1. Adoptive immunotherapy (ADI) of metastasized breast cancer pa-
tients. Process of ADI treatment preparation (PB = Peripheral blood; BM = 
bone marrow; DC = dendritic cell; TC = T cell; MCF-7 = human breast cancer 
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immune cell transfer was well tolerated except for influenza-like 
symptoms in 2 patients.
ii) As early as 1 week after intravenous ADI, tumor antigen-reac-
tive TMCs could be detected in the peripheral blood of about 
50% of the patients (ADI responders). The responding patients 
had received the highest total number of TMCs and harbored 
the lowest tumor burden. Of note, significantly higher levels of 
tumor-specific TMCs had been observed in the BM of patients 
with subsequently positive ADI response compared to non- 
responding patients.
iii) In none of the treated patients with overt bone metastases tu-
mor-reactive TCs were detectable in the peripheral blood after 
ADI. This massively reduced immune responsiveness may be 
related, at least in part, to the increased release of immuno-
suppressive TGF-ß from the bone during the osseous metastatic 
process [36, 58–61].
iv) Finally and most importantly, ADI responders had a signifi-
cantly longer median survival than non-responders (58.6 vs. 
13.6 months; p = 0.009) with 3 out of 16 patients still being alive 
at last follow-up and more than 7 years after ADI [36].
In summary, results hint at a relationship between immune 
 response and cancer prognosis and suggest that preferably BC 
 patients without bone metastases but with immunologic response 
to adoptive TC transfer might benefit from this treatment option. 
Perspectives
The central aim of forthcoming studies will be the control of 
tumor escape mechanisms as described in the preceding chapters. 
Firstly, approaches to deplete or reduce Tregs in their capacity 
to suppress the immune system might substantially improve spon-
taneous or immunotherapy-related tumor defense. One strategy in 
this context may be a combined chemoimmunotherapy of metro-
nomic CTX with an adoptive TC transfer (ADI). This might in-
clude a selection of defined tumor antigens with immune adjuvants 
preventing the re-activation of type-2 TC responses during stimu-
lation. Additionally, new approaches to polyclonal TC expansion 
deserve consideration attempting to replace autologous dendritic 
cells by artificial antigen-presenting cells with improved TC-stimu-
latory properties [62].
Secondly, although still in the experimental phase, recent initia-
tives aim at grafting patients’ primary TCs with a second TC recep-
tor known to recognize a defined tumor antigen [47]. There is 
hope that, in the long run, such engineered tumor-specific TCs 
(CAR-T cells) may be successfully used for adoptive immunother-
apy purposes [63, 64]. 
Thirdly, other current attempts focus on adoptive TC therapy 
with TILs [65–68]. In this context, tumor-reactive TCs are har-
vested from tumor-infiltrated lymph nodes or tumor tissue. In 
metastatic melanoma patients, a transfer of ex vivo activated and 
expanded autologous TILs after a preceding lympho-depleting 
chemotherapy was demonstrated to induce tumor regression in 
about 50% of treated patients [67, 68]. Therefore, a pivotal scien-
tific focus is on the improvement of the tumor antigen recognition 
capacity and, hereby, the therapeutic efficacy of TILs or genetically 
engineered TCs [68–78].
Finally, immune checkpoints are currently the focus of clinical 
research (fig. 2). The expression of ‘cytotoxic T-lymphocyte-associ-
ated antigen 4’ (CTLA-4) on the plasma cell membrane of TCs in-
duces a downregulation of their activity and thereby leads to im-
munosuppression. This effect is mediated by B7 expression on an-
tigen-presenting cells as for example dendritic cells. CTLA-4 is in 
competition with stimulating CD28 for binding to B7. Therefore, 
the expression of one or the other results in TC suppression 
(CTLA-4) or stimulation (CD28).
The ‘programmed cell death protein-1’ (PD-1) is also expressed 
on the plasma cell membrane of TCs. Activated by its ligands PD-L1 
and PD-L2, the generation of Tregs is induced and the activity of 
immune cells is downregulated [79]. PD-L1 is expressed by about 
30% of BC cells and results in relevant immunosuppression [80].
Several immune checkpoint inhibitors are now under clinical 
investigation. Nivolumab, pidilizumab, and pembrolizumab are 
anti-PD-1 antibodies. In metastatic BC, a study with pembroli-
zumab has just been presented [81]. In only 18.5% of the patients 
included a clinical response was detected. Nevertheless, this re-
sponse was long-lasting. Nivolumab showed a clinical benefit in 
patients with malignant melanoma where cases expressing PD-L1 
on the tumor cells were correlated with best responses [82]. In 
those patients, even a prolonged overall survival was observed. BC-
related data is promising although systematic studies are still 
missing.
As described above, blockade of CTLA-4 by antibodies such as 
ipilimumab or tremelimumab enhances the immune reaction 
against tumor cells. In malignant melanoma patients, ipilimumab 
resulted in favorable clinical responses. Consequently, this antibody 
is now being tested in other solid carcinomas, with BC-related data 
still missing. Nevertheless, a combination of checkpoint inhibitors 
might be a promising therapeutic option. In patients with malig-
Fig. 2. Checkpoint inhibitors (CTLA-4 = Cytotoxic T-lymphocyte-associated 
antigen 4; PD-(L)1 = programmed cell death protein (ligand) 1; APC = antigen-
presenting cell; MDSC = myeloid-derived suppressor cell; ROS = reactive oxy-
gen species; TCR = T cell receptor; MEDI 4736/MPDL 3280A = anti-PD-L1 






























nant melanoma, for instance, ipilimumab together with pembroli-
zumab was tested against a solitary ipilimumab therapy. This trial 
showed a relevant benefit in the cohort of patients with combined 
therapy thus justifying further studies [83]. Modulating the im-
mune system, however, is not free of clinical side effects. Suppress-
ing immunosuppressive effects may be related e.g. to several auto-
immune reactions (thyroiditis, colitis, pancreatitis etc.). Therefore, 
thorough clinical observation within trials is mandatory.
All in all, in contrast to other neoplasms such as melanoma, BC 
treatment with immune checkpoint-abrogating agents has only re-
cently become a field of interest. Hence, most clinical trials based 
on immune checkpoint blockade are pilot or phase I/II studies 
[54]. 
Conclusion
In BC, the presence of TILs has been shown to correlate with a 
favorable long-term prognosis primarily of high-grade/highly pro-
liferative lesions. TILs were also associated with a favorable re-
sponse to neoadjuvant and adjuvant anthracycline-based chemo-
therapies. These findings support the addition of immunothera-
peutic strategies to conventional treatment concepts.
In late-stage metastasized BC patients, the adoptive transfer of 
BM TCs (ADI) can induce the presence of tumor antigen-reactive 
TCs in the peripheral blood. This positive immunologic response 
appears to depend significantly on the number of transferred spe-
cific memory TCs and on the absence of BM metastases. Immune 
responders show a significantly prolonged overall survival.
Eventually, future strategies to potentially overcome tumor im-
mune escape should comprise Treg depletion from BM prepara-
tions before their ex vivo activation. Additionally, a functional in-
hibition of the immunocompromising capacity of Tregs or a func-
tional TC stimulation may be achieved either by directly targeted 
antibodies (CTLA-4, PD-1, PD-L1, IL-2 receptor) or by pharmaco-
logic agents such as cyclooxygenase-2 inhibitors or CTX. Besides a 
checkpoint inhibition, immunomodulating metronomic low-dose 
CTX plus ADI appears to be a promising choice of combinatorial 
chemoimmunotherapy. Finally, current developments relating to 
artificial antigen-presenting cells, engineered tumor-specific TCs, 
and TILs should be followed up.
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